abrdn plc Cuts Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

abrdn plc cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 15.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 82,102 shares of the medical research company's stock after selling 15,302 shares during the period. abrdn plc's holdings in IQVIA were worth $19,224,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the stock. Park Place Capital Corp bought a new position in IQVIA during the 3rd quarter valued at about $28,000. Versant Capital Management Inc raised its holdings in shares of IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company's stock worth $26,000 after buying an additional 110 shares during the period. Opal Wealth Advisors LLC bought a new stake in shares of IQVIA during the 2nd quarter worth approximately $27,000. Itau Unibanco Holding S.A. purchased a new position in IQVIA during the 2nd quarter valued at $29,000. Finally, International Assets Investment Management LLC bought a new position in IQVIA in the 2nd quarter valued at $32,000. 89.62% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares of the company's stock, valued at approximately $4,812,302.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.60% of the company's stock.

IQVIA Stock Up 1.6 %

Shares of IQV stock traded up $3.34 during trading hours on Friday, reaching $209.16. 1,461,103 shares of the company's stock were exchanged, compared to its average volume of 1,087,412. IQVIA Holdings Inc. has a fifty-two week low of $181.03 and a fifty-two week high of $261.73. The stock's 50 day moving average is $234.31 and its 200-day moving average is $229.74. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. The company has a market cap of $38.13 billion, a price-to-earnings ratio of 27.16, a P/E/G ratio of 2.11 and a beta of 1.49.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of recent analyst reports. Evercore ISI lowered their target price on shares of IQVIA from $270.00 to $265.00 and set an "outperform" rating for the company in a research note on Tuesday, October 8th. Robert W. Baird lowered their price objective on shares of IQVIA from $256.00 to $223.00 and set a "neutral" rating for the company in a research report on Friday. TD Cowen reduced their target price on shares of IQVIA from $270.00 to $255.00 and set a "buy" rating on the stock in a research report on Friday. Truist Financial lowered their price target on IQVIA from $300.00 to $286.00 and set a "buy" rating for the company in a report on Monday, October 14th. Finally, The Goldman Sachs Group reduced their price objective on IQVIA from $280.00 to $250.00 and set a "buy" rating on the stock in a report on Friday. Four research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, IQVIA has an average rating of "Moderate Buy" and a consensus price target of $261.24.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.